Skip to main content
. 2022 Jun 10;13:867073. doi: 10.3389/fendo.2022.867073

Table 2.

Hormonal data in 14 Algerian patients with 3β-HSD deficiency.

First available analysis Last available analysis (LC-MS/MS)
Patient No. 17OHP (nmol/l)RIA Delta4-A (ng/dl)RIA 17 OH-Preg (nmol/l)(LC MS/MS) DHEA-S (µg/dl)RIA ACTH (pg/ml) Renin (pg/ml) 17OHP LC-MS/MS (nmol/l) 17 OH-Preg LC-MS/MS (nmol/l) DHEA LC-MS/MS (nmol/l) DHEA-S LC-MS/MS (nmol/l)
1/A II-2 60 6.06 140.4 464.38 933 4.12 119.69 30.60 4.82
2/A II-3 0.37* 9.4* 2* <0.3* 1.06* 0.89*
3/B II-1 164.3 5.73 1297 900 2,135 851 2.14
4/B II-2 320 2.34 20.8* 1,000 133 960 1.47
5/C II-3 242 2.24 112.21 538 475 360 4.3 67.57 30.60 3.98
6/D II-1 19.26* 1 159.33 1,105 30.98 1,040 3.5 131.99 77.28 2.88
7/E II-8 7.75* 0.98 127 120 597 1.2 27.65 77.08
8/E II-9 99 4.95 139 5,441.29 540 7.3 92.63
9/F II-1 84.85 0.32 295 150 1 43.02 3.46
10/G II-5 1.83* 2.33* 17.75* 1,080* 16,634 3.5 89.13 27.62 16.63
11/G II-1 804 157 687 10,665 2.14 93 4.37* 20.14
12/H II-2 60 0.01 10.9* 4.32 234.8 802 4.15 127.2 19.35
13/I II-1 73.7 1,500 53 0.08* 1.75* 0.30* 2.9*
14/J II-5 41.6 34.84 3.23*
Reference Range [0.4–3.3] [0.21–3.08] [0.13–13.7] [30–333] [29–38] [360–1,040] [0.49–1.87] [0.13–13.7] 0.5–2 y [0.2–8.7] 1–4 y: [10–530]
5–9 y [80–2,310]

*Analysis performed while on hydrocortisone treatment. 17-OHP, 17 hydroxyprogesterone; 17OH-Preg, 17 hydroxypregnenolone; DHEAS, dehydroepiandrosterone sulfate; ACTH, adrenocorticotrophic hormone; Delta4-A, Delta 4-Androstenedione; LC-MS/MS, Liquid Chromatography coupled to tandem Mass Spectrometry.

Please see Supplementary Table S1 for age-appropriate reference ranges. Hormonal analysis was performed where possible either before starting treatment or within a day of treatment.